Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.57 |
| ▸ | FNTB | P49356 | 4/20 | 0.57 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590521 | 0.91 | FNTA (0.63) | FNTAFNTB | |
| SCHEMBL1758018 | 0.89 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL5562937 | 0.85 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL1757955 | 0.84 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL12590487 | 0.83 | FNTA (0.45) | FNTAFNTBPGGT1B | |
| SCHEMBL6010160 | 0.83 | FNTA (0.78) | FNTAFNTB | |
| SCHEMBL12590524 | 0.82 | FNTA (0.64) | FNTAFNTB | |
| SCHEMBL12590527 | 0.81 | FNTA (0.63) | FNTAFNTB | |
| SCHEMBL11954228 | 0.81 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL1758019 | 0.81 | FNTA (0.67) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490065-B1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINONE AND QUINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | claimed |
| US-7943635-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-17 | — | — | US | disclosed |
| US-7943635-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-17 | — | — | US | disclosed |
| US-7943635-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-17 | — | — | US | disclosed |
| US-20080255191-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | ANGIBAUD PATRICK RENE | 2008-10-16 | — | — | US | disclosed |
| US-20080255191-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | ANGIBAUD PATRICK RENE | 2008-10-16 | — | — | US | disclosed |
| US-20080255191-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | ANGIBAUD PATRICK RENE | 2008-10-16 | — | — | US | disclosed |
| US-7241777-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-7241777-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-7241777-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1490065-B1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINONE AND QUINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050171111-A1 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | US | disclosed |
| EP-1490065-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINONE AND QUINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080058-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA. N.V. (BE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171111-A1 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885PGGT1B 22/4885 |
| US-20080255191-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885PGGT1B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.